Omega Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Omega Therapeutics has a total shareholder equity of $41.4M and total debt of $17.9M, which brings its debt-to-equity ratio to 43.3%. Its total assets and total liabilities are $183.7M and $142.3M respectively.
Key information
43.3%
Debt to equity ratio
US$17.90m
Debt
| Interest coverage ratio | n/a |
| Cash | US$60.03m |
| Equity | US$41.35m |
| Total liabilities | US$142.33m |
| Total assets | US$183.68m |
Recent financial health updates
Recent updates
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'
Mar 31Is Omega Therapeutics (NASDAQ:OMGA) Weighed On By Its Debt Load?
Feb 28
Omega Therapeutics: The Next Weight Loss Drug Runner
Jan 16Omega Therapeutics: Starting 2024 With A Bang
Jan 10Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M
Aug 04Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002
Jul 14Financial Position Analysis
Short Term Liabilities: OMGA's short term assets ($70.9M) exceed its short term liabilities ($24.7M).
Long Term Liabilities: OMGA's short term assets ($70.9M) do not cover its long term liabilities ($117.6M).
Debt to Equity History and Analysis
Debt Level: OMGA has more cash than its total debt.
Reducing Debt: Insufficient data to determine if OMGA's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OMGA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OMGA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.5% each year